PET detection of new lesions early in the course of therapy has been reported to be a strong, independent predictive factor for overall survival in NSCLC patients treated with EGFR inhibitor (Aukema et al., 2010). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.